0001415889-24-015031.txt : 20240531 0001415889-24-015031.hdr.sgml : 20240531 20240531160546 ACCESSION NUMBER: 0001415889-24-015031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyssikatos Joseph P CENTRAL INDEX KEY: 0001967150 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 241009641 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811523849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 4 1 form4-05312024_080541.xml X0508 4 2024-05-29 0001672619 Enliven Therapeutics, Inc. ELVN 0001967150 Lyssikatos Joseph P C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD BOULDER CO 80301 true true false false CHIEF SCIENTIFIC OFFICER 1 Common Stock 2024-05-29 4 M 0 12000 1.12 A 12000 D Common Stock 2024-05-29 4 S 0 9877 21.564 D 2123 D Common Stock 2024-05-29 4 S 0 2123 22.5212 D 0 D Common Stock 1117035 I See footnote Stock Option (right to buy) 1.12 2024-05-29 4 M 0 12000 0 D 2030-06-16 Common Stock 12000 206550 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. This transaction was executed in multiple trades at prices ranging from $21.2024 to $22.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $22.2051 to $22.7331. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. All of the shares subject to this option are fully vested and exercisable as of the date hereof. /s/ Ben Hohl, by power of attorney 2024-05-31